AlzeCure Pharma AB

OSTO:ALZCUR (Sweden)  
kr 1.88 (0%) Jun 20
At Loss
P/B:
9.42
Market Cap:
kr 159.62M ($ 15.24M)
Enterprise V:
kr 140.58M ($ 13.43M)
Volume:
32.68K
Avg Vol (2M):
102.00K
Trade In:
Volume:
32.68K
At Loss
Avg Vol (2M):
102.00K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for AlzeCure Pharma AB ( OSTO:ALZCUR ) from 2018 to Jun 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. AlzeCure Pharma AB stock (OSTO:ALZCUR) PE ratio as of Jun 25 2024 is 0. More Details

AlzeCure Pharma AB (OSTO:ALZCUR) PE Ratio (TTM) Chart

To

AlzeCure Pharma AB (OSTO:ALZCUR) PE Ratio (TTM) Historical Data

Total 1298
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
AlzeCure Pharma AB PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-25 At Loss 2024-04-16 At Loss
2024-06-20 At Loss 2024-04-15 At Loss
2024-06-19 At Loss 2024-04-12 At Loss
2024-06-18 At Loss 2024-04-11 At Loss
2024-06-17 At Loss 2024-04-10 At Loss
2024-06-14 At Loss 2024-04-09 At Loss
2024-06-13 At Loss 2024-04-08 At Loss
2024-06-12 At Loss 2024-04-05 At Loss
2024-06-11 At Loss 2024-04-04 At Loss
2024-06-10 At Loss 2024-04-03 At Loss
2024-06-07 At Loss 2024-04-02 At Loss
2024-06-05 At Loss 2024-04-01 At Loss
2024-06-04 At Loss 2024-03-29 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-27 At Loss 2024-03-21 At Loss
2024-05-24 At Loss 2024-03-20 At Loss
2024-05-23 At Loss 2024-03-19 At Loss
2024-05-22 At Loss 2024-03-18 At Loss
2024-05-21 At Loss 2024-03-15 At Loss
2024-05-20 At Loss 2024-03-14 At Loss
2024-05-17 At Loss 2024-03-13 At Loss
2024-05-16 At Loss 2024-03-12 At Loss
2024-05-15 At Loss 2024-03-11 At Loss
2024-05-14 At Loss 2024-03-08 At Loss
2024-05-13 At Loss 2024-03-07 At Loss
2024-05-10 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss

AlzeCure Pharma AB (OSTO:ALZCUR) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.